OS Therapies, Inc. has successfully closed a private placement financing, raising approximately $6 million. The funds will be used for working capital focused on clinical and regulatory milestones for their lead therapeutic candidate OST-HER2.

OS Therapies is a clinical stage research company focusing on therapeutic treatments for Osteosarcoma, Breast Cancer and other solid tumors with two platform technologies: OST-HER2 to prevent metastasis and OST-tADC to debulk solid tumors. 


ostherapies.com

Health Care

Rockville

OS Therapies

OS Therapies, Inc. raised $6 million in a private placement to support the commercialization of its therapeutic candidate OST-HER2 for metastatic osteosarcoma.

OS Therapies, Inc. raised $6 million in a private placement to support the commercialization of its therapeutic candidate OST-HER2 for metastatic osteosarcoma.

Description

Company Information

Related People

OS Therapies, Inc. raised $6 million in a private placement to support the commercialization of its therapeutic candidate OST-HER2 for metastatic osteosarcoma.

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Related People

Company Information